SB 202190 is a cell permeable pyridinyl imidazole, which acts as a strong inhibitor of SAPK2a/p38 and SAPK2b/p38beta MAP kinases (IC50=280nM and 350nM, respectively). SB 202190 has no effect on the activity of the Erk or SAPK/JNK MAP kinases and is reported to block LPS induced TNF-a and IL-1beta production in mice. The compound is a slightly better inhibitor than the related compound SB 203580.
Solubility:Soluble in DMSO (50mg/ml).
Applications:Specific inhibitor of p38/SAPK2a MAPK and P38b/SAPK2a MAPK activity. Other applications not tested.
Protein Kinase Inhibition Assay:When pre-incubated for five minutes with 0.2ug of SAPK2a/p38 MAPK or SAPK2b/p38beta MAPK, 1-10uM of SB 202190 will inhibit the activity of these kinases 80-95%. The final concentration of SB 202190 needed may depend on the amount of enzyme used. Optimal dilutions to be determined by the researcher.
Storage and Stability:Lyophilized powder may be stored at -20°C. Stable for 12 months after receipt at -20°C. Reconstitute with DMSO. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. Note: Protect from light.
